AUS
NZ
UK
CA
USA
IND
Highlights
- Mayne Pharma enters trading pause after FDA communication
- 12.2% share price drop triggers immediate halt
- Regulatory concerns impact timing of upcoming acquisition
Shares of Australian pharmaceutical company Mayne Pharma (ASX:MYX) were placed in a trading pause after a steep price drop of 12.2%, following concerns raised by the US Food and Drug Administration (FDA) regarding the company’s promotional practices.
The sharp movement in Mayne Pharma’s stock, which fell to AU$5.96 before the pause, was triggered by a letter from the FDA dated 28 April. The agency alleged that Mayne made “false or misleading” claims about the safety profile of its oral contraceptive product, Nextstellis. Specifically, the FDA’s Office of Prescription Drug Promotion pointed out that certain promotional materials presented an underrepresentation of the potential risks associated with the medication.
The letter also highlighted that in January 2022, the FDA had previously issued advisory comments on draft promotional content related to Nextstellis. This suggests that regulators had earlier expressed concerns, which may not have been fully addressed. Mayne Pharma has been given 15 business days to formally respond to the current notice.
This development comes at a critical time for Mayne Pharma, as the company is nearing the completion of a US$430 million (AU$663 million) acquisition by US-based pharmaceutical firm Cosette Pharmaceuticals. The regulatory concerns could raise additional scrutiny or delays around the timing of the transaction.
Investors monitoring the ASX300 index, where Mayne Pharma is a constituent, are closely watching developments that could impact the broader pharmaceutical segment. As a part of the ASX300 index, movements in Mayne Pharma can influence sentiment around healthcare stocks, particularly given the upcoming international deal.
Additionally, this scenario underscores the importance of regulatory compliance and risk disclosures for companies operating in tightly governed sectors like healthcare. For market participants focusing on defensive sectors or consistent performers like ASX dividend stocks, such events serve as a reminder to review underlying business operations beyond surface-level financial metrics.
Mayne Pharma's trading status remains paused as of the latest update, with market participants awaiting further clarity on the company's official response and the FDA’s next steps.
